These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25889527)

  • 1. Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.
    Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf RG; Hall C; Proudman SM; Wiese MD
    Arthritis Res Ther; 2015 Mar; 17(1):48. PubMed ID: 25889527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of rheumatoid arthritis in clinical practice using treat-to-target strategy: Where do we stand in the multi-ethnic Malaysia population?
    Tan BE; Lim AL; Kan SL; Lim CH; Ng YF; Tng SLC; Hassin NS; Chandran L; Hamid NA; Lee YYL
    Rheumatol Int; 2017 Jun; 37(6):905-913. PubMed ID: 28389855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining the acceptable level of physician compliance with a treat-to-target strategy in early rheumatoid arthritis.
    Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf R; Hall C; Proudman SM; Wiese MD
    Int J Rheum Dis; 2017 May; 20(5):576-583. PubMed ID: 26692459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018.
    Xie W; Li J; Zhang X; Sun X; Zhang Z
    Int J Rheum Dis; 2019 Sep; 22(9):1670-1678. PubMed ID: 31297977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Adherence to Protocolized Targeted Intensifications of Disease-modifying Antirheumatic Drugs on Treatment Outcomes in Rheumatoid Arthritis: Results from an Australian Early Arthritis Cohort.
    Wabe NT; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee AT; Spargo LD; Metcalf RG; Hall C; Proudman SM; Wiese MD
    J Rheumatol; 2016 Sep; 43(9):1643-9. PubMed ID: 27422892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treat-to-target approach in daily clinical practice in Pakistani patients with early Rheumatoid Arthritis.
    Farman S; Ahmad NM; Saeed MA; Asad K; Shabbir G
    J Coll Physicians Surg Pak; 2015 Feb; 25(2):129-33. PubMed ID: 25703758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study.
    Brenol CV; da Chakr RM; Andrade NP; Toni M; Laurindo IM; Brenol JC; Xavier RM
    Clin Rheumatol; 2015 Oct; 34(10):1781-5. PubMed ID: 25771853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recently diagnosed rheumatoid arthritis patients benefit from a treat-to-target strategy: results from the DREAM registry.
    Steunebrink LM; Vonkeman HE; ten Klooster PM; Hoekstra M; van Riel PL; van de Laar MA
    Clin Rheumatol; 2016 Mar; 35(3):609-15. PubMed ID: 26852313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring patients with rheumatoid arthritis in routine care: experiences from a treat-to-target strategy using the DANBIO registry.
    Hetland ML; Jensen DV; Krogh NS
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-141-6. PubMed ID: 25365104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation.
    Markusse IM; Dirven L; Han KH; Ronday HK; de Sonnaville PB; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):446-53. PubMed ID: 26239288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjustment in the clinical practice of treat-to-target guidelines for rheumatoid arthritis: Results of the ToARCan study.
    Naranjo A; Cáceres L; Hernández-Beriaín JÁ; Francisco F; Ojeda S; Talaverano S; Nóvoa-Medina J; Martín JA; Delgado E; Trujillo E; Álvarez F; Magdalena L; Rodríguez-Lozano C
    Reumatol Clin; 2016; 12(1):34-8. PubMed ID: 25869900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating rheumatoid arthritis to target: a Canadian patient survey.
    Haraoui B; Bensen W; Thorne C; Wade J; Deamude M; Prince J; Légaré J
    J Clin Rheumatol; 2014 Mar; 20(2):61-7. PubMed ID: 24561407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in the activity of rheumatoid arthritis as the consequence of treat-to-target strategy: eight-year data from 2009 to 2016.
    Xie W; Li J; Zhang X; Li G; Hao Y; Zhao J; Wang L; Sun X; Fan Y; Zhang Z
    Clin Exp Rheumatol; 2018; 36(5):820-828. PubMed ID: 29533754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Earlier time to remission predicts sustained clinical remission in early rheumatoid arthritis--results from the Canadian Early Arthritis Cohort (CATCH).
    Kuriya B; Xiong J; Boire G; Haraoui B; Hitchon C; Pope J; Thorne JC; Tin D; Keystone EC; Bykerk V;
    J Rheumatol; 2014 Nov; 41(11):2161-6. PubMed ID: 25274902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: The RA T2T PORTAL study.
    Benham H; Rutherford M; Kirby S; Stebbings S; White D; Sim D; Harrison A
    Int J Rheum Dis; 2019 May; 22(5):874-879. PubMed ID: 30793870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.